搜索
 > 【IGF-I】重组蛋白信息

IGF-I信息

英文名称:Insulin-like growth factor I
中文名称:胰岛素样生长因子-I
靶点别称:Insulin-like growth factor I,Somatomedin-C,IBP1,IGF1,MGF,Mechano growth factor,IGF-I
上市药物数量:0
临床药物数量:8
最高研发阶段:临床三期

IGF-I产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
IG1-H4269
Human
Human IGF-I Protein,N-Fc Tag,HEK293 expressed

IGF-I 分子别名

IGF-I,IGF1A,somatomedin C,MGF

IGF-I 分子背景

Insulin-like growth factor 1 (IGF-1) is also known as somatomedin C, IGF1A, IGFI, sulfation factor, and is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. A synthetic analog of IGF-1, mecasermin is used for the treatment of growth failure. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7649 daltons. IGF-1 is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. IGF-1 binds to at least two cell surface receptors: the Insulin-like growth factor 1 receptor, abbreviated as "IGF1R", and the insulin receptor. The IGF-1 receptor seems to be the "physiologic" receptor - it binds IGF-1 at significantly higher affinity than the IGF-1 that is bound to the insulin receptor. Like the insulin receptor, the IGF-1 receptor is a receptor tyrosine kinase - meaning it signals by causing the addition of a phosphate molecule on particular tyrosines. Its primary action is mediated by binding to its specific receptor IGF1R, present on many cell types in many tissues. Binding to the IGF1R, a receptor tyrosine kinase, initiates intracellular signaling; IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. Insulin-like growth factor 1 has been shown to bind and interact with all the IGF-1 Binding Proteins (IGFBPs), of which there are six (IGFBP1-6). Specific references are provided for interactions with IGFBP3, IGFBP4 and IGFBP7.

IGF-I 参考文献

IGF-I临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Mecasermin (Teva Pharmaceutical Industries) CEP-120; KW-6151 临床三期 Cephalon, 默沙东, Kyowa Hakko 肾衰竭, 肌萎缩性脊髓侧索硬化症, 多发性硬化症, 外周神经病变
Xentuzumab BI-836845 临床二期 勃林格殷格翰 非小细胞肺癌, 前列腺癌, 乳腺癌, 实体瘤 详情
HF-0299 HF-0299; NPC-01,NPC01,HF0299 临床一期 LTT Institute, Newron Pharmaceutical 神经痛 详情
Dusigitumab MEDI-573 临床二期 MedImmune 乳腺癌 详情
FP-008 FP-008,FP008; FP 008 临床前 Foresee Pharmaceuticals 糖尿病视网膜病变
IGF-drug conjugates (IGF Oncology) 临床前 IGF Oncology 癌症
ARX-201 ARX-201,ARX 201,ARX201 临床二期 Ambrx 生长素缺乏症 详情
AEW-541 AEW-541; NVP-AEW-541; NVP-AEW541-NX; NVP-AEW541-NX7 临床一期 诺华 实体瘤, 血液病

消息提示

请输入您的联系方式,再点击提交!

确定